Advanced

Montelukast does not affect exercise performance at subfreezing temperature in highly trained non-asthmatic endurance athletes

Sue-Chu, M; Sandsund, M; Holand, B and Bjermer, Leif LU (2000) In International Journal of Sports Medicine 21(6). p.424-428
Abstract
Anti-leukotriene therapy represents a new principle in asthma treatment. As elite athletes can have asthma, this double-blind, placebo-controlled, randomised cross-over study investigated the effect of 10 mg oral montelukast, a specific and potent cysteinyl leukotriene receptor antagonist, on physiological responses to submaximal and maximal aerobic exercise at -15 degrees C in 14 non-asthmatic highly trained endurance male athletes (maximal oxygen uptake [VO2 max] > 70 ml x kg(-1) x min(-1)). Heart rate, capillary blood lactate, minute ventilation with tidal volume and breathing frequency, respiratory exchange ratio and oxygen uptake were measured during the warm-up run of 10 min at 50%, runs of 10 min at 90% and 5 min at 80% VO2max,... (More)
Anti-leukotriene therapy represents a new principle in asthma treatment. As elite athletes can have asthma, this double-blind, placebo-controlled, randomised cross-over study investigated the effect of 10 mg oral montelukast, a specific and potent cysteinyl leukotriene receptor antagonist, on physiological responses to submaximal and maximal aerobic exercise at -15 degrees C in 14 non-asthmatic highly trained endurance male athletes (maximal oxygen uptake [VO2 max] > 70 ml x kg(-1) x min(-1)). Heart rate, capillary blood lactate, minute ventilation with tidal volume and breathing frequency, respiratory exchange ratio and oxygen uptake were measured during the warm-up run of 10 min at 50%, runs of 10 min at 90% and 5 min at 80% VO2max, and a timed run to exhaustion. Spirometry was performed at baseline, at four hours after tablet ingestion, after warm-up and exercise at 80% VO2max, and in the post exercise period. Compared to placebo, montelukast did not increase baseline FEV1, have a beneficial effect on physiological performance variables, or increase the mean (SD) running time to exhaustion (montelukast: 332.3 [45.8] s, placebo: 340.1 [53.3] s, P = 0.22). These findings do not suggest the need for disallowing the use of this drug by asthmatic athletes. (Less)
Please use this url to cite or link to this publication:
author
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Montelukast, leukotriene receptor antagonists, physical performance, endurance athletes
in
International Journal of Sports Medicine
volume
21
issue
6
pages
424 - 428
publisher
Georg Thieme Verlag
external identifiers
  • pmid:10961518
  • scopus:0033860413
ISSN
0172-4622
DOI
10.1055/s-2000-3838
language
English
LU publication?
no
id
c0e0ffe0-003d-41d1-b048-ae060b5c1b7c (old id 1116644)
date added to LUP
2008-07-02 09:30:40
date last changed
2017-01-01 07:13:54
@article{c0e0ffe0-003d-41d1-b048-ae060b5c1b7c,
  abstract     = {Anti-leukotriene therapy represents a new principle in asthma treatment. As elite athletes can have asthma, this double-blind, placebo-controlled, randomised cross-over study investigated the effect of 10 mg oral montelukast, a specific and potent cysteinyl leukotriene receptor antagonist, on physiological responses to submaximal and maximal aerobic exercise at -15 degrees C in 14 non-asthmatic highly trained endurance male athletes (maximal oxygen uptake [VO2 max] > 70 ml x kg(-1) x min(-1)). Heart rate, capillary blood lactate, minute ventilation with tidal volume and breathing frequency, respiratory exchange ratio and oxygen uptake were measured during the warm-up run of 10 min at 50%, runs of 10 min at 90% and 5 min at 80% VO2max, and a timed run to exhaustion. Spirometry was performed at baseline, at four hours after tablet ingestion, after warm-up and exercise at 80% VO2max, and in the post exercise period. Compared to placebo, montelukast did not increase baseline FEV1, have a beneficial effect on physiological performance variables, or increase the mean (SD) running time to exhaustion (montelukast: 332.3 [45.8] s, placebo: 340.1 [53.3] s, P = 0.22). These findings do not suggest the need for disallowing the use of this drug by asthmatic athletes.},
  author       = {Sue-Chu, M and Sandsund, M and Holand, B and Bjermer, Leif},
  issn         = {0172-4622},
  keyword      = {Montelukast,leukotriene receptor antagonists,physical performance,endurance athletes},
  language     = {eng},
  number       = {6},
  pages        = {424--428},
  publisher    = {Georg Thieme Verlag},
  series       = {International Journal of Sports Medicine},
  title        = {Montelukast does not affect exercise performance at subfreezing temperature in highly trained non-asthmatic endurance athletes},
  url          = {http://dx.doi.org/10.1055/s-2000-3838},
  volume       = {21},
  year         = {2000},
}